Medline (NasdaqGS:MDLN) Q4 2025 Earnings call February 25, 2026 09:30 AM ET Speaker14Please be advised that today's conference is being recorded. I would like to hand the conference over to Karen King, Global Head of Investor Relations. Please go ahead.Speaker8Welcome to Medline's fourth quarter and full year 2025 earnings conference call. This morning, we issued our earnings release and shared supplemental materials. Joining me on today's call are Jim Boyle, our Chief Executive Officer, and Mike Drazin, ou ...

The above list of factors is not exhaustive or necessarily in order of importance. For additional information on identifying factors that may cause actual results to vary materially from those stated in forward-looking statements, see the discussion under "Part I, Item IA. Risk Factors" in the company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. You should read this presentation completely and with the understanding that actual future results m ...

CAPITAL MARKETS PRESENTATION 1Q 2026 SAFE HARBOR COMMENTS AND FORWARD-LOOKING STATEMENTS 2 This presentation contains "forward-looking" statements related to O-I Glass, Inc. ("O-I Glass" or the "Company") within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements reflect the Company's current expectations and projections about future events at the time, and thus involve uncer ...

Heather Rosentrater President and Chief Executive Officer Q4 2025 Earnings February 25, 2026 Call Participants 2 Kevin Christie Senior VP, Chief Financial Officer, Treasurer, and Regulatory Affairs Officer Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our current expectations for future financial performance and cash flows, capital expenditures, financing plans, our current plans or objectives for future operations and other factors that may ...

Summary of Savara's Conference Call Company Overview - **Company**: Savara - **Focus**: Clinical stage biopharmaceutical company specializing in rare respiratory diseases - **Product**: Developing MOLBREEVI, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for autoimmune pulmonary alveolar proteinosis (APAP) [1][3] Recent Progress - **FDA Submission**: BLA (Biologics License Application) accepted by the FDA with a priority review assigned, PDUFA date set for August 22nd [3][4] - **Clinical Trials**: Positive results from the global phase III study (IMPALA-2) for APAP, supporting confidence in the approval process [3][6] Unmet Need and Treatment Landscape - **Current Situation**: No approved therapies for APAP in the U.S. and Europe; existing treatment involves a mechanical procedure (whole lung lavage) that is not standardized and only available in select centers [8][10] - **MOLBREEVI's Advantage**: Addresses the underlying pathophysiology of APAP by activating macrophages, improving gas exchange and surfactant homeostasis [11] Market Potential - **Patient Population**: Estimated 5,500 diagnosed patients in the U.S., equating to approximately 16 patients per million, which is within the published range of 6-26 patients per million for this rare disease [14][15] - **Treatment Accessibility**: All identified patients could potentially benefit from MOLBREEVI upon approval, with physicians indicating willingness to prescribe it regardless of disease severity [15][19] Commercial Strategy - **Field Force**: Plans to establish a commercial field force of approximately 30 customer-facing personnel, focusing on the top 500 accounts that manage two-thirds of the patient population [20][21] - **Partnerships**: Selected PANTHERx Rare as the exclusive specialty pharmacy, leveraging their experience in rare diseases and existing relationships with pulmonary offices [22][23] Financial Position - **Cash Reserves**: As of the last report, Savara has $264 million in cash, with potential access to an additional $150 million in non-dilutive financing upon FDA approval [26][27] - **Funding Strategy**: Includes a royalty agreement and a debt facility to support operations and commercialization efforts [27] Additional Insights - **Launch Preparations**: Ongoing disease awareness campaigns and educational initiatives are being conducted to prepare for the commercialization of MOLBREEVI [24][25] - **Long-term Outlook**: The company is well-funded and positioned for a successful launch, with a strong focus on addressing the needs of APAP patients [27][28]

ASP Isotopes (NasdaqCM:ASPI) Conference February 25, 2026 09:05 AM ET Company ParticipantsAnna Berry - HostPaul Mann - Chairman and CEOAnna Berryeveryone to the 90th Emerging Growth Conference and day one of our two-day virtual investor conference. I'm Anna Berry. Just a few notes. Today, we're running until about 4:50 P.M. Eastern. When we switch to the next company, you'll see a black screen for a moment. Don't go anywhere. That's just us moving to the next presentation. If you do experience downtime for ...

Lowe’s (NYSE:LOW) Q4 2026 Earnings call February 25, 2026 09:00 AM ET Company ParticipantsBrandon Sink - EVP and CFOJonathan Matuszewski - SVPJoseph McFarland III - EVP of StoresKate McShane - Managing DirectorKate Pearlman - Vice President of Investor Relations and TreasurerMarvin Ellison - Chairman, President, and CEOWilliam Boltz - EVP of MerchandisingConference Call ParticipantsBrian Nagel - Managing Director and Senior AnalystChristopher Horvers - Senior AnalystMichael Lasser - Equity Research AnalystP ...

Postal Realty Trust (NYSE:PSTL) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Company ParticipantsAndrew Spodek - CEOJeremy Garber - PresidentJordon Cooperstein - Senior VP and Corporate Counsel Securities and Capital MarketsSteve Bakke - EVP and CFOConference Call ParticipantsAnthony Paolone - Senior AnalystJohn Hecht - AnalystJohn Kim - AnalystOperatorGreetings, welcome to Postal Realty Trust Fourth Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. A question and ...

Euroholdings (NasdaqCM:EHLD) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Company ParticipantsAnastasios Aslidis - Chief Strategy Officer and TreasurerAristides Pittas - Chairman and CEOAthina Atalioti - CFOOperatorThank you for standing by, ladies and gentlemen, and welcome to the Euroholdings Conference Call on the fourth quarter 2025 financial results. We have with us Mr. Aristidis Pittas, Chairman and Chief Executive Officer, Ms. Athina Atalioti, Chief Financial Officer, and Mr. Tasos Aslidis, Ch ...

International General Insurance (NasdaqCM:IGIC) Q4 2025 Earnings call February 25, 2026 09:00 AM ET Company ParticipantsRobin Sidders - Head of Investor RelationsWaleed Jabsheh - President and CEOWasef Jabsheh - Executive ChairmanConference Call ParticipantsMichael Phillips - Md and Senior AnalystRoland Meyer - Research AnalystOperatorGood day, welcome to the International General Insurance Holdings fourth quarter and full year 2025 financial results conference call. All participants are in a listen-only mo ...